From current immunosuppressive strategies to clinical tolerance of allografts

Transplant International

Volumn 20, Issue 1, 2007, Pages 12-24

  Golshayan, Dela ^a   Buhler, Leo ^b   Lechler, Robert I ^c   Pascual, Manuel ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Allorecognition; Clinical tolerance; Immunosuppression; Transplantation tolerance

Indexed keywords

15 DEOXYSPERGUALIN; ABATACEPT; ALEMTUZUMAB; AZATHIOPRINE; BASILIXIMAB; BELATACEPT; BUSULFAN; CALCINEURIN INHIBITOR; CD40 ANTIGEN; CD40 LIGAND; CD40 LIGAND MONOCLONAL ANTIBODY; CD45RB ANTIGEN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DACLIZUMAB; DIPHTHERIA TOXIN; EVEROLIMUS; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD3; MONOCLONAL ANTIBODY CD3 DIPHTHERIA TOXIN CONJUGATE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; POLYCLONAL ANTIBODY; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY;

ALLOGRAFT; ALLOIMMUNITY; ALLOTRANSPLANTATION; ANTIGEN RECOGNITION; BONE MARROW; CHIMERA; CLINICAL PRACTICE; CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG TARGETING; GRAFT RECIPIENT; GRAFT REJECTION; HEMATOPOIETIC CELL; HLA MATCHING; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT REJECTION; LUNG EMBOLISM; NONHUMAN; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; T CELL DEPLETION; T LYMPHOCYTE ACTIVATION; THROMBOSIS; TRANSIENT ISCHEMIC ATTACK; TRANSPLANTATION TOLERANCE;

EID: 33845612363     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2006.00401.x     Document Type: Review

References (125)

1. Silkensen JR. Long-term complications in renal transplantation. J Am Soc Nephrol 2000; 11: 582.
2. Cohen D, Galbraith C. General health management and long-term care of the renal transplant recipient. Am J Kidney Dis 2001; 38(6 Suppl. 6):S10.
3. Sayegh MH, Carpenter CB. Transplantation 50 years later - progress, challenges, and promises. N Engl J Med 2004; 351: 2761.
4. Hernandez-Fuentes MP, Lechler RI. Chronic graft loss. Immunological and non-immunological factors. Contrib Nephrol 2005; 146: 54.
5. Pascual M, Theruvath T, Kawai T, Tolkoff-Rubin N, Cosimi AB. Strategies to improve long-term outcomes after renal transplantation. N Engl J Med 2002; 346: 580.
6. Magee CC, Pascual M. Update in renal transplantation. Arch Intern Med 2004; 164: 1373.
7. Billingham RE, Brent L, Medawar PB. Actively acquired tolerance of foreign cells. Nature 1953; 172: 603.
8. Gould DS, Auchincloss Jr H. Direct and indirect recognition: the role of MHC antigens in graft rejection. Immunol today 1999; 20: 77.
9. Rogers NJ, Lechler RI. Allorecognition. Am J Transplant 2001; 2: 97.
10. Jiang S, Herrera O, Lechler RI. New spectrum of allorecognition pathways: implications for graft rejection and transplantation tolerance. Curr Opin Immunol 2004; 16: 550.
11. Liu Z, Sun Y, Xi Y, et al. Contribution of direct and indirect recognition pathways to T cell alloreactivity. J Exp Med 1993; 177: 1643.
12. Benichou G, Valujskikh A, Heeger PS. Contributions of direct and indirect T cell alloreactivity during allograft rejection in mice. J Immunol 1999; 162: 352.
13. Auchincloss Jr H, Lee R, Shea S, Markowitz JS, Grusby MJ, Glimcher LH. The role of indirect recognition in initiating rejection of skin grafts from major histocompatibility complex class II-deficient mice. Proc Natl Acad Sci USA 1993; 90: 3373.
14. Vella JP, Spadafora-Ferreira M, Murphy B, et al. Indirect allorecognition of major histocompatibility complex allopeptides in human renal transplant recipients with chronic graft dysfunction. Transplantation 1997; 64: 795.
15. Frasca L, Amendola A, Hornick P, et al. Role of donor and recipient antigen-presenting cells in priming and maintaining T cells with indirect allospecificity. Transplantation 1998; 66: 1238.
16. Lee RS, Grusby MJ, Glimcher LH, Winn HJ, Auchincloss Jr H. Indirect recognition by helper cells can induce donor-specific cytotoxic T lymphocytes in vivo. J Exp Med 1994; 179: 865.
17. Steele DJR, Laufer TM, Smiley ST, et al. Two levels of help for B cell alloantibody production. J Exp Med 1996; 183: 699.
18. Lakkis FG, Arakelov A, Konieczny BT, Inoue Y. Immunologic 'ignorance' of vascularized organ transplants in the absence of secondary lymphoid tissue. Nat Med 2000; 6: 686.
19. Golshayan D, Lechler R. Priming of alloreactive T cells - where does it happen? Eur J Immunol 2004; 34: 3301.
20. Gallucci S, Lolkema M, Matzinger P. Natural adjuvants: endogenous activators of dendritic cells. Nat Med 1999; 11: 1249.
21. Janeway Jr CA, Medzhitov R. Innate immune recognition. Annu Rev Immunol 2002; 20: 197.
22. Lanzavecchia A, Sallusto F. Regulation of T cell immunity by dendritic cells. Cell 2001; 106: 263.
23. Mason PD, Robinson CM, Lechler RI. Detection of donor-specific hyporesponsiveness following the failure of human renal allografts. Kidney Int 1996; 50: 1019.
24. Hornick PI, Yacoub MH, Rose ML, Batchelor R, Lechler RI. Assessment of the contribution that direct allorecognition makes to the progression of chronic cardiac transplant rejection in humans. Circulation 1998; 97: 1257.
25. Baker RJ, Hernandez-Fuentes MP, Brookes PA, Chaudhry AN, Lechler RI. The role of the allograft in the induction of donor-specific T cell hyporesponsiveness. Transplantation 2001; 72: 480.
26. Lechler RI, Batchelor JR. Restoration of immunogenicity to passenger cell-depleted kidney allografts by the addition of donor strain dendritic cells. J Exp Med 1982; 155: 31.
27. Lechler RI, Batchelor JR. Immunogenicity of retransplanted rat kidney allografts. Effect of inducing chimerism in the first recipient and quantitative studies on immunosuppression of the second recipient. J Exp Med 1982; 156: 1835.
28. Liu Z, Colovai AI, Tugulea S, et al. Indirect recognition of donor HLA-DR peptides in organ allograft rejection. J Clin Invest 1996; 98: 1150.
29. Ciubotariu R, Liu Z, Colovai AI, et al. Persistent allopeptide reactivity and epitope spreading in chronic rejection of organ allografts. J Clin Invest 1998; 101: 398.
30. Hornick PI, Mason PD, Baker RJ, et al. Significant frequencies of T cells with indirect anti-donor specificity in heart graft recipients with chronic rejection. Circulation 2000; 101: 2405.
31. Baker RJ, Hernandez-Fuentes MP, Brookes PA, Chaudhry AN, Cook HT, Lechler RI. Loss of direct and maintenance of indirect alloresponses in renal allograft recipients: implications for the pathogenesis of chronic allograft nephropathy. J Immunol 2001; 167: 7199.
32. Lee RS, Yamada K, Houser SL, et al. Indirect recognition of allopeptides promotes the development of cardiac allograft vasculopathy. Proc Natl Acad Sci USA 2001; 98: 3276.
33. Reznik SI, Jaramillo A, SivaSai KS, et al. Indirect allorecognition of mismatched donor HLA class II peptides in lung transplant recipients with bronchiolitis obliterans syndrome. Am J Transplant 2001; 1: 228.
34. Herrera OB, Golshayan D, Tibbott R, et al. A novel pathway of alloantigen presentation by dendritic cells. J Immunol 2004; 173: 4828.
35. Mitchison NA, O'Malley C. Three-cell-type clusters of T cells with antigen-presenting cells best explain the epitope linkage and noncognate requirements of the in vivo cytolytic response. Eur J Immunol 1987; 17: 1579.
36. Bluestone JA. Costimulation and its role in organ transplantation. Clin Transplant 1996; 10: 104.
37. Schwartz RH. Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell 1992; 71: 1065.
38. Watts TH, DeBenedette MA. T cell costimulatory molecules other than CD28. Curr Opin Immunol 1999; 11: 286.
39. Harding FA, McArthur JG, Gross JA, Raulet DH, Allison JP. CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature 1992; 356: 607.
40. Denton MD, Magee CC, Sayegh MH. Immunosuppressive strategies in transplantation. Lancet 1999; 353: 1083.
41. Wong W, Venetz JP, Tolkoff-Rubin N, Pascual M. 2005 immunosuppressive strategies in kidney transplantation: which role for calcineurin inhibitors? Transplantation 2005; 80: 289.
42. Madsen JC, Yamada K, Allan JS, et al. Transplantation tolerance prevents cardiac allograft vasculopathy in major histocompatibility complex class I-disparate miniature swine. Transplantation 1998; 65: 304.
43. Lechler RI, Chai JG, Marelli-Berg F, Lombardi G. The contributions of T-cell anergy to peripheral T-cell tolerance. Immunology 2001; 103: 262.
44. Lechler RI, Garden OA, Turka LA. The complementary roles of deletion and regulation in transplantation tolerance. Nat Rev Immunol 2003; 3: 147.
45. Reinsmoen NL, Matas AJ. Evidence that improved late renal transplant outcome correlates with the development of in vitro donor antigen-specific hyporeactivity. Transplantation 1993; 55: 1017.
46. Kirk AD, Burkly LC, Batty DS, et al. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nat Med 1999; 5: 686.
47. Douek DC, Koup RA. Evidence for thymic function in the elderly. Vaccine 2000; 18: 1638.
48. Sykes M. Mixed chimerism and transplant tolerance. Immunity 2001; 14: 417.
49. Ildstad ST, Sachs DH. Reconstitution with syngeneic plus allogeneic or xenogeneic bone marrow leads to specific acceptance of allografts or xenografts. Nature 1984; 307: 168.
50. Manilay JO, Pearson DA, Sergio JJ, Swenson KG, Sykes M. Intrathymic deletion of alloreactive T cells in mixed bone marrow chimeras prepared with a non myeloablative conditioning regimen. Transplantation 1998; 66: 96.
51. Wekerle T, Sayegh MH, Hill J, et al. Extrathymic T cell deletion and allogeneic stem cell engraftment induced with costimulatory blockade is followed by central T cell tolerance. J Exp Med 1998; 187: 2037.
52. Wekerle T, Kurtz J, Ito H, et al. Allogeneic bone marrow transplantation with co-stimulatory blockade induces macrochimerism and tolerance without cytoreductive host treatment. Nat Med 2000; 6: 464.
53. Adams AB, Durham MM, Kean L, et al. Costimulation blockade, busulfan, and bone marrow promote titratable macrochimerism, induce transplantation tolerance, and correct genetic hemoglobinopathies with minimal myelosuppression. J Immunol 2001; 167: 1103.
54. Myburgh JA, Smit JA, Mieny CJ, Mason JA. Hepatic allotransplantation in the baboon. 3. The effects of immunosuppression and administration of donor-specific antigen after transplantation. Transplantation 1971; 12: 202.
55. Kawai T, Poncelet A, Sachs DH, et al. Long-term outcome and alloantibody production in a non-myeloablative regimen for induction of renal allograft tolerance. Transplantation 1999; 68: 1767.
56. Kawai T, Abrahamian G, Sogawa H, et al. Costimulatory blockade for induction of mixed chimerism and renal allograft tolerance in nonhuman primates. Transplant Proc 2001; 33: 221.
57. Kawai T, Cosimi AB, Wee SL, et al. Effect of mixed hematopoietic chimerism on cardiac allograft survival in cynomolgus monkeys. Transplantation 2002; 73: 1757.
58. Kawai T, Sogawa H, Boskovic S, et al. CD154 blockade for induction of mixed chimerism and prolonged renal allograft survival in nonhuman primates. Am J Transplant 2004; 4: 1391.
59. Sayegh MH, Fine NA, Smith JL, Rennke HG, Milford EL, Tilney NL. Immunologic tolerance to renal allografts after bone marrow transplants from the same donors. Ann Intern Med 1991; 114: 954.
60. Spitzer TR, Delmonico F, Tolkoff-Rubin N, et al. Combined histocompatibility leukocyte antigen-matched donor bone marrow and renal transplantation for multiple myeloma with end stage renal disease: the induction of allograft tolerance through mixed lymphohematopoietic chimerism. Transplantation 1999; 68: 480.
61. Buhler LH, Spitzer TR, Sykes M, et al. Induction of kidney allograft tolerance after transient lymphohematopoietic chimerism in patients with multiple myeloma and end-stage renal disease. Transplantation 2002; 74: 1405.
62. Cosimi AB, Sachs DH. Mixed chimerism and transplantation tolerance. Transplantation 2004; 77: 943.
63. Strober S, Dhillon M, Schubert M, et al Acquired immune tolerance to cadaveric renal allografts. A study of three patients treated with total lymphoid irradiation. N Engl J Med 1989; 321: 28.
64. Strober S, Benike C, Krishnaswamy S, Engleman EG, Grumet FC. Clinical transplantation tolerance twelve years after prospective withdrawal of immunosuppressive drugs: studies of chimerism and anti-donor reactivity. Transplantation 2000; 69: 1549.
65. Millan MT, Shizuru JA, Hoffmann P, et al. Mixed chimerism and immunosuppressive drug withdrawal after HLA-mismatched kidney and hematopoietic progenitor transplantation. Transplantation 2002; 73: 1386.
66. Sakaguchi S. Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 2004; 22: 531.
67. Wood KJ, Sakaguchi S. Regulatory T cells in transplantation tolerance. Nat Rev Immunol 2003; 3: 199.
68. Lechler R, Ng WF, Steinman RM. Dendritic cells in transplantation: friend or foe? Immunity 2001; 14: 357.
69. Barratt-Boyes SM, Thomson AW. Dendritic cells: tools and targets for transplant tolerance. Am J Transplant 2005; 5: 2807.
70. Hubbard WJ, Moore JK, Contreras JL, et al. Phenotypic and functional analysis of T-cell recovery after anti-CD3 immunotoxin treatment for tolerance induction in Rhesus macaques. Hum Immunol 2001; 62: 479.
71. Contreras JL, Wang PX, Eckhoff DE, et al. Peritransplant tolerance induction with anti-CD3-immunotoxin: a matter of proinflammatory cytokine control. Transplantation 1998; 65: 1159.
72. Kirk AD, Mannon RB, Kleiner DE, et al. Results from a human renal allograft tolerance trial evaluating T-cell depletion with alemtuzumab combined with deoxyspergualin. Transplantation 2005; 80: 1051.
73. Knechtle SJ, Vargo D, Fechner J, et al. FN18-CRM9 immunotoxin promotes tolerance in primate renal allografts. Transplantation 1997; 63: 1.
74. Armstrong N, Buckley P, Oberley T, et al. Analysis of primate renal allografts after T-cell depletion with anti-CD3-CRM9. Transplantation 1998; 66: 5.
75. Thomas JM, Eckhoff DE, Contreras JL, et al. Durable donor-specific T and B-cell tolerance in rhesus macaques induced with peritransplantation anti-CD3 immunotoxin and deoxyspergualin: absence of chronic allograft nephropathy. Transplantation 2000; 69: 2497.
76. Hirshberg B, Preston EH, Xu H, et al. Rabbit antithymocyte globulin induction and sirolimus monotherapy supports prolonged islet allograft function in a nonhuman primate islet transplantation model. Transplantation 2003; 76: 55.
77. Torrealba JR, Fernandez LA, Kanmaz T, et al. Immunotoxin-treated Rhesus monkeys: a model for renal allograft chronic rejection. Transplantation 2003; 76: 524.
78. Calne R, Friend P, Moffatt S, et al. Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients. Lancet 1998; 351: 1701.
79. Calne R, Moffatt SD, Friend PJ, et al. Campath 1H allows low-dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients. Transplantation 1999; 68: 1613.
80. Swanson SJ, Hale DA, Mannon RB, et al. Kidney transplantation with rabbit antithymocyte globulin induction and sirolimus monotherapy. Lancet 2002; 360: 1662.
81. Shapiro R, Jordan ML, Basu A, et al. Kidney transplantation under a tolerogenic regimen of recipient pretreatment and low-dose postoperative immunosuppression with subsequent weaning. Ann Surg 2003; 238: 520.
82. Wells AD, Li XC, Li Y, et al. Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance. Nat Med 1999; 5: 1303.
83. Tian L, Lu L, Yuan Z, Lamb JR, Tam PK. Acceleration of apoptosis in CD4+CD8+ thymocytes by rapamycin accompanied by increased CD4+CD25+ T cells in the periphery. Transplantation 2004; 77: 183.
84. Battaglia M, Stabilini A, Roncarolo MG. Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. Blood 2005; 105: 4743.
85. Lazarovits AI, Poppema S, Zhang Z, et al. Prevention and reversal of renal allograft rejection by antibody against CD45RB. Nature 1996; 380: 717.
86. Rothstein DM, Livak MF, Kishimoto K, et al. Targeting signal 1 through CD45RB synergizes with CD40 ligand blockade and promotes long term engraftment and tolerance in stringent transplant models. J Immunol 2001; 166: 322.
87. Waldmann H, Bemelman F, Cobbold S. Tolerance induction with CD4 monoclonal antibodies. Novartis Found Symp 1998; 215: 146; discussion 152, 186.
88. Sayegh M, Turka L. The role of T cell costimulatory activation pathways in transplant rejection. N Eng J Med 1998; 338: 1813.
89. Zheng XX, Sanchez-Fueyo A, Sho M, Domenig C, Sayegh MH, Strom TB. Favourably tipping the balance between cytopathic and regulatory T cells to create transplantation tolerance. Immunity 2003; 19: 503.
90. Graca L, Honey K, Adams E, Cobbold SP, Waldmann H. Anti-CD154 therapeutic antibodies induce infectious transplantation tolerance. J Immunol 2000; 165: 4783.
91. Monk NJ, Hargreaves RE, Marsh JE, et al. Fc-dependent depletion of activated T cells occurs through CD40L-specific antibody rather than costimulation blockade. Nat Med 2003; 9: 1275.
92. Mackey MF, Barth Jr RJ, Noelle RJ. The role of CD40/CD154 interactions in the priming, differentiation, and effector function of helper and cytotoxic T cells. J Leukoc Biol 1998; 63: 418.
93. + T cells can trigger allograft rejection. J Immunol 2000; 165: 1111.
94. Pfeiffer S, Lii GL, Azimzadeh AM, Atkinson J, Newman R, Pierson RN. Monotherapy with anti-CD40 ligand antibody (IDEC 131) for non-human primate allograft heart transplantation. J Heart Lung Transplant 2001; 20: 250.
95. Kenyon NS, Chatzipetrou M, Masetti M, et al. Long-term survival and function of intrahepatic islet allografts in Rhesus monkeys treated with humanised anti-CD154. Proc Natl Acad Sci USA 1999; 96: 8132.
96. Schuler W, Bigaud M, Brinkmann V, et al. Efficacy and safety of ABI793, a novel human anti-human CD154 monoclonal antibody, in cynomolgus monkey renal allotransplantation. Transplantation 2004; 77: 717.
97. Elster EA, Hale DA, Mannon RB, Cendales LC, Swanson SJ, Kirk AD. The road to tolerance: renal transplant tolerance induction in nonhuman primate studies and clinical trials. Transplant Immunol 2004; 13: 87.
98. Kawai T, Andews D, Colvin RB, Sachs DH, Cosimi AB. Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nat Med 2000; 6: 114.
99. Knosalla C, Gollackner B, Cooper DK. Anti-CD154 monoclonal antibody and thromboembolism revisited. Transplantation 2002; 74: 416.
100. Buhler L, Alwayn IP, Appel JZ, Robson SC, Cooper DK. Anti-CD154 monoclonal antibody and thromboembolism. Transplantation 2001; 71: 491.
101. Ossevvoort MA, Ringers J, Kuhn EM, et al. Prevention of renal allograft rejection in primates by blocking the B7/CD28 pathway. Transplantation 1999; 68: 1010.
102. Kirk AD, Tadaki DK, Celniker A, et al. Induction therapy with monoclonal antibodies specific for CD80 and CD86 delays the onset of acute renal allograft rejection in nonhuman primates. Transplantation 2001; 72: 377.
103. Birsan T, Hausen B, Higgins JP, et al. Treatment with humanised monoclonal antibodies against CD80 and CD86 combined with sirolimus prolongs renal allograft survival in cynomolgus monkeys. Transplantation 2003; 75: 2106.
104. Judge TA, Wu Z, Zheng XG, Sharpe AH, Sayegh MH, Turka LA. The role of CD80, CD86, and CTLA4 in alloimmune responses and the induction of long-term allograft survival. J Immunol 1999; 162: 1947.
105. Levisetti MG, Padrid PA, Szot GL, et al. Immunosuppressive effects of human CTLA-4 Ig in a non human primate model of allogeneic pancreatic islet transplantation. J Immunol 1997; 159: 5187.
106. Larsen CP, Elwood ET, Alexander DZ, et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 1996; 381: 434.
107. Kirk AD, Harlan DM, Armstrong NN, et al. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci USA 1997; 94: 8789.
108. Adams AB, Shirasugi N, Durham MM, et al. Calcineurin inhibitor-free CD28 blockade-based protocol protects allogeneic islets in nonhuman primates. Diabetes 2002; 51: 265.
109. Adams AB, Shirasugi N, Jones TR, et al. Development of a chimeric anti-CD40 monoclonal antibody that synergizes with LEA29Y to prolong islet allograft survival. J Immunol 2005; 174: 542.
110. Vincenti F, Larsen C, Durrbach A, et al. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 2005; 353: 770.
111. Larsen CP, Pearson TC, Adams AB, et al. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant 2005: 5:443.
112. Perez VL, Van Parijs L, Biuckians A, Zheng XX, Strom TB, Abbas AK. Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. Immunity 1997; 6: 411.
113. Salomon B, Bluestone JA. Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu Rev Immunol 2001; 19: 225.
114. Tsai MK, Ho HN, Chien HF, Ou-Yang P, Lee CJ, Lee PH. The role of B7 ligands (CD80 and CD86) in CD152-mediated allograft tolerance: a crosscheck hypothesis. Transplantation 2004; 77: 48.
115. Mason D. A very high level of cross-reactivity is an essential feature of the T-cell receptor. Immunol Today 1998; 19: 395.
116. Lombardi G, Sidhu S, Daly M, Batchelor JR, Makgoba W, Lechler RI. Are primary alloresponses truly primary? Int Immunol 1990; 2: 9.
117. Pantenburg B, Heinzel F, Das L, Heeger PS, Valujskikh A. T cells primed by Leishmania major infection cross-react with alloantigens and alter the course of allograft rejection. J Immunol 2002; 169: 3686.
118. Adams AB, Williams MA, Jones TR, et al. Heterologous immunity provides a potent barrier to transplantation tolerance. J Clin Invest 2003; 111: 1887.
119. Wu Z, Bensinger SJ, Zhang J, et al. Homeostatic proliferation is a barrier to transplantation tolerance. Nat Med 2004; 10: 87.
120. Lakkis FG, Sayegh MH. Memory T cells: a hurdle to immunologic tolerance. J Am Soc Nephrol 2003; 14: 2402.
121. Adams AB, Pearson TC, Larsen CP. Heterologous immunity: an overlooked barrier to tolerance. Immunol Rev 2003; 196: 147.
122. Hernandez-Fuentes MP, Warrens AN, Lechler RI. Immunologic monitoring. Immunol Rev 2003; 196: 247.
123. Brouard S, Dupont A, Giral M, et al. Operationally tolerant and minimally immunosuppressed kidney recipients display strongly altered blood T cell clonal regulation. Am J Transplant 2005; 5: 330.
124. Baeten D, Louis S, Braud C, et al. Phenotypically and functionally distinct CD8+ lymphocyte populations in long-term drug-free tolerance and chronic rejection in human kidney graft recipients. J Am Soc Nephrol 2006; 17: 294.
125. Li Y, Koshiba T, Yoshizawa A, et al. Analyses of peripheral blood mononuclear cells in operational tolerance after paediatric living donor liver transplantation. Am J Transplant 2004; 4: 2118.